Press Releases | Regeneron Pharmaceuticals Inc.
WEBLibtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer. Sep 9. Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO. Aug 26.
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Regeneron Pharmaceuticals, Inc. (REGN) Latest Stock News
WEBGet the latest Regeneron Pharmaceuticals, Inc. (REGN) stock news and headlines to help you in your trading and investing decisions.
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBAug 1, 2024 · Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.
INVESTORS & MEDIA - newsroom.regeneron.com
WEB1 day ago · When Regeneron 's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite ® …
Novel Regeneron Bispecific Antibodies Show Encouraging Anti …
WEBSep 10, 2022 · Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors. First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer.
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® (aflibercept) Injection in patients with …
Regeneron Pharmaceuticals: Delivering Life-transforming Medicines
WEBRegeneron News: Sep 20th. Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old. Follow us: View our FDA-approved medicines. We move science to medicine because our world is meant for more . We are a company founded in the pursuit of more.
Regeneron, Sanofi Get FDA OK of Dupixent for COPD — Update
WEB1 day ago · RBC said it sees an ultimate world-wide COPD sales opportunity topping $6.5 billion, bringing overall Dupixent sales to more than $26 billion at their peak. Tarrytown, N.Y., biotechnology company ...
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic …
WEB1 day ago · Currently, Regeneron's stock is trading at $1,063.05, up 2.22 percent, and Sanofi's stock is trading at $57.90, up 1.60 percent on the Nasdaq. SHARE THIS POST FACEBOOK